Industry news
-
The First Russia COVID-19 Drug Will Deliver to the Country’s Hospitals in June
03 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group will deliver 60,000 courses of Avifavir to Russian hospitals in June. Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
-
In St. Petersburg, Creates a Vaccine against Coronavirus Based on Influenza Virus
03 June 2020
Researchers from the St. Petersburg-based Smorodintsev Research Institute of Influenza are working on a vaccine against the novel coronavirus infection on the basis of a flu virus, a spokesman for the institute told TASS on June 2.
-
Russian Ministry of Health Approves the First COVID-19 Drug Avifavir
02 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group announce that Avifavir has received a temporary registration certificate from the Ministry of Health of the Russian Federation. Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
-
The First Russia COVID-19 Drug Will Deliver to the Country’s Hospitals in June
02 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group will deliver 60,000 courses of Avifavir to Russian hospitals in June. Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
-
COVID-19: EMA Calls for High-quality Observational Studies
01 June 2020
For observational studies of real world data in COVID-19, EMA calls for transparency for protocols and results, and collaboration between researchers, to ensure high-quality, powerful studies. High-quality observational research of real world data collected during the pandemic can be an important complement to the results of randomised clinical trials in providing evidence on the safety and effectiveness of vaccines and treatments for COVID-19. Such research is also critical to understand how exposure to certain medicines can affect the risk or the severity of infection with the virus.
-
Singapore Pharmaceutical Output up 86% this Year
29 May 2020
Pharmaceutical output in Singapore has spiked 86% so far this year, official data showed, while export data for April showed pharmaceutical shipments surged 174% from the same month a year earlier, albeit from a low base.
-
Russian Chemists Create a Medicine for Parkinson’s and Alzheimer’s Diseases
29 May 2020
Chemists of the Ural Federal University and the Sri Venkateswar University (Tirupati, India) have synthesized new neuroprotective antioxidants based on derivatives of α-methyl-L-DOPA and urea. The results of the research are presented in the journal Bioorganic Chemistry.
-
mRNA-based Vaccine Technology – Leading in Development for COVID-19
28 May 2020
Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19, with eighteen candidates currently in development globally, according to GlobalData.
-
COVID-19: Russia’s Vector Picked Three Promising Vaccine Prototypes for Research
28 May 2020
The Vector State Center for Virology and Biotechnology (Vector Institute) plans to begin clinical trials of its coronavirus vaccine in late June this year, the Center’s CEO Rinat Maksyutov told TASS, adding that the Institute picked three promising vaccine prototypes for further research.
-
Sponsored In the Race Towards a Vaccine, Manufacturing and QC Must Keep Pace
27 May 2020
The growing global demand for new therapeutics and vaccines, which has intensified due to the COVID-19 pandemic, is creating a seismic shift in development and manufacturing.
